Debiopharm Joins Discussions With International Health Organisations to Fight Anti-Microbial Resistance at the 2023 World AMR Congress
6.9.2023 15:00:00 EEST | Business Wire | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced their participation in the keynote panel and antibiotic development track sessions at the 2023 World AMR conference from September 7th – 8th, 2023.
Debiopharm’s panelist Morgane Vanbiervliet, Market Intelligence & Business Development Manager, Infectious Diseases, is part of the AMR preparedness keynote panel to be moderated by Bruce Y. Lee from Forbes and involving representatives from the CDC, Menarini Group, IFPMA and the AMR Action Fund. A further Debiopharm-sponsored breakout session, moderated by Dr. Ricardo Chaves, Executive Medical Director, will feature Dr. L. Clifford McDonald, Associate Director for Science in the Division of Healthcare Quality Promotion at the CDC, explaining the relevance of novel microbiome-sparing antibiotics in combating AMR, and the potential need for new regulatory approval and reimbursement pathways.*
“It’s important to harness these open dialogues between public organizations and the infectious disease industry experts at World AMR to produce action that can prepare us to face the emerging wave of resistant infections,” explained Morgane Vanbiervliet, Market Intelligence & Business Development Manager, Infectious Diseases, Debiopharm. “We know that uncontrollable infectious diseases are everybody’s business, and that our preparation efforts must involve the reinforcement of prevention measures, better stewardship education, and sustainable market pathways for new effective treatments.”
“The CDC recognizes the importance of the human microbiome as it provides key resistance to human colonization with multidrug-resistant pathogens. Along with products that will reduce the degree of colonization (i.e. pathogen reduction), or drugs that will restore the microbiome, we need therapeutic antibiotics that spare the microbiome, by being highly-selective for only specific pathogens.” expressed Dr. L. Clifford McDonald, Associate Director for Science in the Division of Healthcare Quality Promotion, CDC.
Last year’s special report from the CDC on the impact of COVID-19 on antimicrobial resistance revealed that 6 of the 18 most alarming bacterial menaces cost the US more that $4.6 billion each year and thousands of human lives.4 The agency’s 18 bacterial and fungal threats include 2 pathogens for which Debiopharm is currently developing new antibiotics: Neisseria gonorrhoeae and methicillin-resistant Staphylococcus aureus. Debiopharm’s FabI inhibitor therapies are part of a new pathogen-specific antibiotic class that is being researched for its capacity to effectively treat a single type of bacteria and thereby preserve the microbiome and avoid subsequent spread of AMR.
|
World AMR 2023 Session details |
Congress agenda |
Speakers |
|
Keynote panel Sept. 7th 08:35 EST
|
How can we push AMR to the forefront of preparedness? |
Morgane Vanbiervliet, Market Intelligence & Business Development Manager, Infectious Diseases, Debiopharm + other invited speakers
|
|
Panel discussion Sept. 7th 11:00–11:30 EST
|
Antibiotic Development stream
The public health case for microbiome-sparing antibiotics: Potential need for new pathways in regulatory approval and reimbursement
|
Moderator:
Executive Medical Director Debiopharm
Speaker: Dr.L. Clifford McDonald, Associate Director for Science in the Division of Healthcare Quality Promotion, CDC
|
About afabicin
Afabicin (Debio 1450) is Debiopharm’s first-in-class FabI inhibitor against Staphylococcus spp., whose methicillin-resistant Staphylococcus aureus (MRSA) strains are high on the WHO global priority pathogen list and deemed a “serious threat” by the CDC. Afabicin can be administered orally or IV and selectively targets Staphylococcus ’ essential bacterial fatty acid biosynthesis. Promising results have been obtained in a comparative double-blind Phase 2 trial with afabicin in acute bacterial skin and skin structure infections. Currently, a Phase 2 trial in bone and joint infections is being conducted in several countries comparing afabicin to standard antibiotics.
About Debio 1453
Analogous to afabicin, the preclinical compound Debio 1453 is a potential first in class pathogen-specific drug targeting the essential bacterial fatty acid biosynthesis pathway. Debio 1453 is administered orally to treat Neisseria gonorrhoeae , the bacteria causing the sexually transmitted disease gonorrhea, a cause of serious and permanent health issues including infertility, ectopic pregnancy, cardiovascular and neurological problems.
Debiopharm’s fight against antimicrobial resistance
Debiopharm, an innovation-focused, Swiss biopharmaceutical company is one of the few privately owned companies developing novel class antibiotics to combat hard-to-treat infections. Through their unique partnership-based business model, the company is advancing pathogen-specific antibiotics from early stage through phase II clinical research with afabicin, specifically targeting staphylococci, being the most clinically advanced for the treatment of bone and joint infections. As a result of high selectivity, FabI inhibitors specifically target selected pathogens while preserving intestinal microbiota and meet all four WHO 2020 innovation criteria: new chemical class, new target, new mode of action and no cross-resistance to other antibiotic classes.
For more information, please visit www.debiopharm.com
We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews
References
[1] Morrison L, Zembower TR. Antimicrobial resistance. Gastrointest Endosc Clin N Am. 2020 Oct;30(4):619-635.
[2] Antimicrobial resistance surveillance in Europe 2023–2021 data. www.who.int/europe/publications/i/item/9789289058537
[3] CDC Antibiotic resistance threats in the United States, 2019. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf
[4] COVID-19 U.S. Impact on Antimicrobial Resistance. https://www.cdc.gov/drugresistance/pdf/covid19-impact-report-508.pdf
Disclosures
* Speaker disclosures: Dr. McDonald has no relevant financial or non-financial relationships to disclose. The findings and conclusions of this presentation are those of the author and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the U.S. Department of Health and Human Services. Any use of trade names and commercial sources is for identification only and does not imply endorsement by the Centers for Disease Control and Prevention or the U.S. Department of Health and Human Services.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230906072351/en/
Contact information
Debiopharm Contact
Dawn Bonine
Head of Communication
dawn.bonine@debiopharm.com
Tel: +41 (0)21 321 01 11
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 14:00:00 EET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 13:00:00 EET | Press release
HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP) Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 Constraints Not Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. C
Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 10:15:00 EET | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char
DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 09:18:00 EET | Press release
Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers compared to currently available technologies. This in turn is boosting expectations
EdgeConneX Looks to Enter Swedish Market as Part of European Data Center Expansion Strategy27.2.2026 09:05:00 EET | Press release
EdgeConneX®, an EQT portfolio company with an extensive Pan-European data center footprint, looks to expand its presence with a new site located in Skellefteå, Sweden. The data center site will be acquired from Lyten, a global company that specializes in lithium-sulfur batteries and energy storage. The site would support EdgeConneX broader strategy to expand digital infrastructure capacity across the Nordics. Subject to the completion of applicable administrative and regulatory processes, EdgeConneX will look to develop a data center campus with potential capacity of up to one gigawatt in support of future AI and cloud computing workloads. Upon completion, the data center campus would be one of the largest facilities in Europe that would be primarily powered by renewable energy. “Sweden represents an attractive long‑term market for digital infrastructure investment. The country’s access to renewable energy, stable power grid, technical workforce and strong sustainability framework alig
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom